Newamsterdam Pharma Company N.V. ((NAMS)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NewAmsterdam Pharma Company N.V. is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study.’ The study aims to evaluate whether Obicetrapib can enhance antioxidant absorption in blood and eye tissue, potentially offering a novel approach to improving antioxidant levels in the body.
The intervention being tested is a drug called Obicetrapib, administered at a dosage of 10mg. It is designed to assess its impact compared to a placebo, focusing on the absorption of antioxidants in healthy volunteers.
This Phase 2 study follows a randomized, double-blind, placebo-controlled parallel design. Participants are randomly assigned to receive either Obicetrapib or a placebo, with both participants and investigators blinded to the assignments. The primary goal is to explore basic scientific questions about antioxidant absorption.
The study began on May 13, 2025, with primary completion expected in the coming months. The latest update was submitted on October 15, 2025, indicating ongoing recruitment and progress in the trial.
For investors, this study could influence NewAmsterdam Pharma’s stock performance, as positive results may enhance the company’s market position in the antioxidant treatment space. The competitive landscape includes other firms exploring similar antioxidant therapies, which could impact investor sentiment and market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.